C-X-C chemokine receptor type 4 (CXCR4) is a Class A GPCR receptor crucial for immune cell trafficking and is widely implicated in cancer progression and metastasis. CXCR4 is expressed on various cells, including immune and cancer cells, and interacts with its ligand, CXCL12 (also known as SDF-1). This interaction facilitates tumor growth and metastasis by promoting cell migration, survival, and angiogenesis, ultimately allowing cancer cells to spread and establish secondary sites within the body. By disrupting the CXCR4/CXCL12 interaction, therapies can potentially limit tumor progression, inhibit metastasis, and improve patient outcomes in several types of cancer.
We have designed a molecule, ABS241003, that specifically targets CXCR4, acting as a selective binder. ABS241003 binds to CXCR4, preventing its interaction with CXCL12 and thereby disrupting the signaling pathway that typically promotes cancer cell migration and survival. By inhibiting this interaction, ABS241003 may hinder metastatic progression and enhance the effectiveness of other therapeutic interventions. This mechanism suggests that ABS241003 could be a valuable addition to cancer therapy regimens, particularly in strategies aimed at preventing metastasis and reducing tumor spread.
Reviews
There are no reviews yet.